Key Calls (Wednesday): Upgrades, Downgrades & Initiations

 

 

 

 

 

 


1580572w


(Bloomberg) — Changes since prior close.

Upgrade

UPGRADES: 

  • Discovery (DISCA) upgraded to outperform at Credit Suisse; PT $40
  • Ellie Mae (ELLI) upgraded to buy at Roth Capital; Price Target $100
  • Ferrari (RACE) upgraded to hold at SocGen; PT $130
  • Intuitive Surgical (ISRG) raised to overweight at Piper Jaffray
  • McDonald’s (MCD) upgraded to buy at Guggenheim; PT Set to $200
  • Myriad Genetics (MYGN) upgraded to overweight at Piper Jaffray; PT $53
  • PSEG (PEG) upgraded to buy at UBS; PT $60
  • Ra Pharmaceuticals (RARX) raised to strong buy at Raymond James; PT $28
  • Southern Co (SO) upgraded to neutral at BofAML

Downgrade

DOWNGRADES: 

  • Antero Midstream Partners (AM) cut to market perform at Raymond James
  • Church & Dwight (CHD) downgraded to sell at Deutsche Bank
  • Clorox (CLX) downgraded to sell at Deutsche Bank
  • International Paper (IP) downgraded to neutral at Goldman; PT $53
  • Kimberly-Clark (KMB) downgraded to sell at Deutsche Bank
  • MEG Energy (MEG CN) cut to sector perform at National Bank; PT C$12
  • Trevena (TRVN) downgraded to hold at Jefferies; PT $1
  • Vipshop Holdings ADRs (VIPS) downgraded to neutral at JPMorgan; PT $6

 

INITIATION

INITIATIONS:

  • Agnico Eagle Mines (AEM CN) rated new overweight at Barclays; PT $39
  • Air Lease (AL) rated new buy at Seaport; PT $60
  • Akoustis Technologies (AKTS) rated new overweight at Piper Jaffray
  • Audentes Therapeutics (BOLD) rated new neutral at Guggenheim
  • Avrobio (AVRO) rated new buy at Guggenheim; PT $35
  • Barrett Business Services (BBSI) rated new buy at Sidoti; PT $95
  • Crispr Therapeutics (CRSP) rated new outperform at Wells Fargo; PT $65
  • Cryoport (CYRX) rated new buy at B Riley FBR; PT $22
  • Editas (EDIT) rated new neutral at Guggenheim
  • Everest Re (RE) rated new neutral at Citi; PT $237
  • Floor & Decor (FND) rated new buy at Citi; PT $44
  • Franco-Nevada (FNV CN) rated new overweight at Barclays; PT $70
  • Freeport (FCX) rated new underweight at Barclays; PT $12
  • Goldcorp (G CN) rated new overweight at Barclays; PT $14
  • Hudbay Minerals (HBM CN) rated new overweight at Barclays; PT $8
  • Lamb Weston (LW) reinstated buy at William O’Neil & Co Incorporated
  • Lumber Liquidators (LL) rated new neutral at Citi; PT $15
  • Magna International (MG CN) rated new equal-weight at Barclays
  • Mellanox (MLNX) rated new buy at BofAML
  • Micron (MU) rated new neutral at Piper Jaffray; PT $48
  • Molina (MOH) rated new in line at Evercore ISI; PT $158
  • National Energy Services Reunited (NESRU) new outperform at Evercore ISI
  • Newmont (NEM) rated new overweight at Barclays; PT $34
  • OceanaGold (OGC CN) rated new equal-weight at Barclays; PT C$4
  • Quanterix (QTRX) rated new buy at Canaccord; PT $27
  • Royal Gold (RGLD) rated new equal- weight at Barclays; PT $78
  • Sangamo (SGMO) rated new buy at Guggenheim; PT $18
  • Spark Therapeutics (ONCE) rated new buy at Guggenheim; PT $70
  • Take-Two (TTWO) rated new outperform at Bernstein; PT $175
  • Teck Resources (TECK/B CN) rated new overweight at Barclays; PT C$38
  • Wellcare (WCG) rated new outperform at Evercore ISI; PT $365
  • Wheaton Precious Metals (WPM CN) rated new overweight at Barclays
  • Yamana Gold (YRI CN) rated new underweight at Barclays; PT $2.50
  • Zynex (ZYXI) rated new buy at B Riley FBR; PT $7

 


 

Tuesday, October 9th: Upgrades, Downgrades & Initiations. 

Monday, October 8th: Upgrades, Downgrades & Initiations. 

 

 


-R.W.N II, yours in 322.

Screen Shot 2018-10-05 at 11.41.04 PM

Banyan Capital Management, LLC (“BCM”) is a publisher, not a registered investment advisor, and nothing in BCM’s newsletter is intended, and it should not be construed, to be investment advice. BCM’s newsletter is for informational use only. Any mention in BCM’s newsletter of a particular security, index, derivative, or other instrument is neither a recommendation by BCM to buy, sell, or hold that security, index, derivative, or other instrument, nor does it constitute an opinion of BCM (or of any of its officers, employees, agents or representatives) as to the suitability of that security, index, derivative or other instrument for any particular purpose. BCM is not in the business of giving investment advice or advice regarding the suitability for any purpose of any security, index, derivative, other instrument or trading strategy and nothing in BCM’s newsletter should be so used or relied upon. BCM is not acting as your financial advisor nor in a fiduciary capacity, with regard to any securities, index, derivative or other instrument referred to in BCM’s newsletter. Also, no representation is made concerning the tax implications in any applicable jurisdiction regarding any securities, index, derivative or other instrument and BCM is not advising you in respect of the tax implications. All opinions and estimates in the newsletters are given as of the date of their publication on the BCM’s website and are subject to change and BCM does not assume any obligation to update the newsletters or to reference any such changes. BCM hereby expressly disclaims any and all representations and warranties that: (a) the content of its newsletters is correct, accurate, complete, reliable or a guaranty of future performance; (b) any of its newsletters will be available at any particular time or place, or in any particular medium; and (c) that any omission or error in any of its newsletters will be corrected. BCM shall not be liable for any errors or omissions made in its newsletters or for any inaccuracies in its assumptions. BCM specifically disclaims liability for any losses or damages (incidental, consequential or otherwise) that may arise from the newsletters and that are either used or relied upon by anyone for any reason, including without limitation, the use of the newsletters in the preparation of any financial books and records. Although from time to time BCM’s newsletter may link to or promote others’ websites or services, BCM is not responsible for and does not control those websites or services. BCM’s newsletter is published and distributed in accordance with applicable United States and foreign copyright and other laws. Without the prior written consent of BCM, no person or entity, directly or indirectly, may copy, reproduce, recompile, decompile, disassemble, reverse engineer, distribute, publish, display, perform, modify, upload to create derivative works from, transmit, or in any way exploit all or any part of BCM’s website, its newsletter, or any other material belonging to BCM.Without the prior written consent of BCM, no person or entity, directly or indirectly, may offer all or any part of BCM’s website, its newsletter, or any other material belonging to BCM for sale, nor may any person or entity, directly or indirectly, distribute all or any part of BCM’s website, its newsletter, or any other material belonging to BCM over or by means of any medium.Without the prior written consent of BCM, no person or entity, directly or indirectly, may make all or any part of BCM’s website, its newsletter, or any other material belonging to BCM, available as part of or in connection with another website, whether by hyperlink, framing on the Internet or otherwise. At any given time BCM’s principals may or may not have a financial interest in any or all of the securities and instruments discussed herein. At any given time BCM’s principals may or may not have a financial interest in any or all of the securities and instruments discussed herein.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.